isabelobrien, Author at European Medical Journal - Page 47 of 70

Staying out of hot water on social media

As the UK PMCPA publishes its first social media guidance for pharmaceutical companies, what can they do to avoid traps when it comes to posting online?

Going for gold in gynaecological cancers

The pharmaceutical industry is being urged to take action to bridge the access gap for women with gynaecological cancers, but what steps are needed to change the game?

CSL Behring’s Karen Pinachyan on the future of healthcare

Karen Pinachyan, Head of Medical Affairs for Europe, CSL Behring, talks to Isabel O’Brien about the power of personalised medicine, overhauling healthcare and why it is key to know your own mind

Oncology under the microscope

This infographic explores the intricacies of the oncology market, assessing its impact on patients, its global market share and the new drugs to watch in the oncology space.

Spotlight: January-April 2023

GOLD looks back at some of the top news stories from the pharmaceutical industry over the last few months, covering landmark therapy approvals, insulin price cuts and much more.

Pharma in the US

Exploring the current state of the US pharmaceutical market, this article investigates the balance between innovation and access to care in the country.

Advancing diversity in clinical trials

This infographic explores the diversity of patient populations in US clinical trials and the pharmaceutical industry’s efforts to address this and improve outcomes.

GSK's Judy Stewart on vaccine preventable diseases

GSK’s Judy Stewart discusses her ambition to work in pharmaceuticals and make a difference to public health, the vast GSK vaccine pipeline, leadership and the importance of work-life balance.

Tipping the scales of KOL success

How can pharma maximise the impact of key opinion leaders in the ever-evolving digital world?

Attracting diverse talent into STEM

This infographic explores how the pharmaceutical industry is attracting and supporting the future STEM workforce with DE&I initiatives.